Despite LIMD1’s key homoeostatic functions, the level of ablation in LUAD/LUSC and the large disease burden in lung cancer, there are currently no targeted therapies for LIMD1-deficient cancers. This evidence concerns the gene LIMD1 and lung carcinoma.